Arjun Agarwal Sells 395 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 395 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $69.69, for a total value of $27,527.55. Following the completion of the sale, the senior vice president directly owned 16,899 shares of the company’s stock, valued at $1,177,691.31. The trade was a 2.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Arjun Agarwal also recently made the following trade(s):

• On Friday, June 12th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The shares were sold at an average price of $69.72, for a total transaction of $659,481.48.
• On Monday, May 18th, Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock. The shares were sold at an average price of $59.07, for a total transaction of $607,830.30.

Oruka Therapeutics Trading Down 1.5%

NASDAQ ORKA traded down $1.03 during trading on Monday, hitting $68.86. The company had a trading volume of 1,002,319 shares, compared to its average volume of 1,071,721. Oruka Therapeutics, Inc. has a one year low of $10.77 and a one year high of $91.00. The company has a market cap of $4.15 billion, a price-to-earnings ratio of -35.49 and a beta of -0.25. The company’s fifty day moving average is $63.71 and its 200-day moving average is $44.31.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.04. As a group, equities analysts anticipate that Oruka Therapeutics, Inc. will post -2.06 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. BTIG Research reiterated a “buy” rating and set a $151.00 target price on shares of Oruka Therapeutics in a report on Thursday, May 14th. Wedbush set a $165.00 price target on Oruka Therapeutics in a research report on Monday, April 27th. UBS Group upped their price target on Oruka Therapeutics from $75.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, April 28th. Barclays raised their price objective on Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a research report on Monday, April 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Tuesday, April 21st. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $131.30.

Institutional Trading of Oruka Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Fairmount Funds Management LLC grew its stake in shares of Oruka Therapeutics by 9.9% in the third quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock worth $71,252,000 after acquiring an additional 333,340 shares during the last quarter. Viking Global Investors LP purchased a new position in shares of Oruka Therapeutics in the 3rd quarter worth about $51,280,000. Deep Track Capital LP boosted its stake in Oruka Therapeutics by 38.4% in the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock worth $51,051,000 after purchasing an additional 735,983 shares in the last quarter. Vanguard Group Inc. grew its position in Oruka Therapeutics by 38.1% during the 4th quarter. Vanguard Group Inc. now owns 2,453,530 shares of the company’s stock valued at $74,366,000 after purchasing an additional 676,865 shares during the last quarter. Finally, RTW Investments LP increased its stake in Oruka Therapeutics by 5.8% during the 4th quarter. RTW Investments LP now owns 2,058,148 shares of the company’s stock valued at $62,382,000 after purchasing an additional 112,499 shares in the last quarter. Hedge funds and other institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.